|Bid||146.90 x 1200|
|Ask||147.00 x 1100|
|Day's range||136.59 - 148.54|
|52-week range||119.01 - 497.49|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||4.34|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||220.00|
Shares of Moderna (NASDAQ: MRNA) were jumping 7.5% higher as of 11:30 a.m. ET on Friday. Instead, Moderna appears to be benefiting from the overall stock market bounce. Good news for the overall stock market tends to be good news for Moderna.
The S&P 500 has fallen by 17% since the start of the year, the Nasdaq Composite is down by almost 28%, and many popular growth stocks have been struggling, including big names like Tesla (NASDAQ: TSLA) and Moderna (NASDAQ: MRNA), which have performed even worse than the indexes. Beta is a measure of an investment's volatility based on how closely its performance mirrors that of the broader market. If a stock's beta value is greater than 1, it has in the past exhibited wider swings than the market -- and you can generally expect that it will continue to do so.
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) both delivered major returns for investors in the early days of the coronavirus vaccine race. Moderna's vaccine entered the market in December of 2020. Novavax's vaccine began winning authorizations a year later -- but isn't yet approved in the United States.